Sharemaestro Newsreel

If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever

Key Points Warren Buffett steered the Berkshire Hathaway holding company to market-crushing returns for 60 years. He often said everyday investors could do well by simply buying an exchange-traded fund that tracks a diversified index like the S&P 500. In February 2014, he specifically …

AMGEN TO OPEN NEW SCIENCE & INNOVATION CENTER IN GENOME VALLEY, HYDERABAD

New Site Will Support Global Research and Development Capabilities and Advance Scientific Research HYDERABAD, India, Aug. 12, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to open a new Science and Innovation Center at Genome Valley in Hyderabad. The center will join Amgen's …

Align Technology Prevails in China Patent Infringement Action

Align Technology (ALGN) disclosed late Tuesday that the Jinan Intermediate People's Court in China issued a judgment in its favor, in a patent infringement action against Angelalign Technology's operating subsidiaries in China.The company provides an orthodontic treatment system Silver Upgrade to read this MT …

Stock futures little changed as traders await inflation report

[Wall Street-Street Sign] P_Wei/E+ via Getty Images Stock index futures were muted on Wednesday as traders turned their attention to a closely watched consumer inflation report that could offer fresh clues on the Federal Reserve's policy path. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.01%, S&P 500 …

Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH

(RTTNews) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports. Alamar Biosciences Inc. (ALMR) Alamar Biosciences is a proteomics company that has develops a liquid biopsy platform …

Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed?

Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, …

Projeções de Resultados: Pfizer Inc (PFE) — LPA e Crescimento de Receita

Projeções de Resultados: DaVita Inc (DVA) — LPA e Crescimento de Receita

One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses

Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was …

3 Healthcare Stocks with Open Questions

3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over …

Does Medtronic (MDT) Still Trade At A Discount After Its CE Mark Win?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic stock has delivered a 20.8% gain over the past three years, yet current checks suggest it now sits close to its estimated …

Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?

In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer …

1 Profitable Stock with Impressive Fundamentals and 2 We Turn Down

1 Profitable Stock with Impressive Fundamentals and 2 We Turn Down While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, "Your margin is my opportunity". Not …

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q2 Earnings Call Vertex Pharmaceuticals' second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue …

Align Technology Prevails in China Patent Infringement Action Against Angelalign

SAN JOSE, Calif. & TEMPE, Ariz., August 12, 2026--(BUSINESS WIRE)--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a …

Takeda Pharmaceutical (TSE:4502) Wins ORZEYFUL Approval, Where Does Fair Value Sit?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after U.S. regulators approved ORZEYFUL for adult narcolepsy type 1, and the company also issued new impairment …

Stocks Supported by Renewed Middle East Optimism

The S&P 500 Index ($SPX) (SPY) today is up +0.04%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.32%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.07%. September E-mini S&P futures (ESU26) are up +0.02%, and September E-mini Nasdaq futures (NQU26) …

AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision …

Stryker’s (SYK) Comeback Quarter Looks Great, But At What Cost?

Stryker (NYSE:SYK) turned in one of its stronger quarters in recent memory on July 30, with sales climbing 9.4% to $6.6 billion and reported EPS jumping 44.1% to $3.30. The numbers arrive as the company works its way back from a cyber incident that …

Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)?

Thermo Fisher Scientific (NYSE:TMO) mostly sells the instruments and supplies that let other companies do science, not the treatments themselves. So when the company said on July 29 that it had launched the PPD CorEvitas Vitiligo Registry on July 14, to track how patients …

AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in …

Top Research Reports for Meta, Texas Instruments & CrowdStrike

Tuesday, August 11, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Texas Instruments Inc. (TXN) and CrowdStrike Holdings, Inc. (CRWD), as well …

Earnings To Watch: Cardinal Health (CAH) Reports Q2 Results Tomorrow

Earnings To Watch: Cardinal Health (CAH) Reports Q2 Results Tomorrow Healthcare distributor and services company Cardinal Health (NYSE:CAH) will be announcing earnings results this Tuesday before market hours. Here's what to expect. Cardinal Health missed analysts' revenue expectations last quarter, reporting revenues of $60.94 …

Cardinal Health Bolts Higher Despite Mixed Earnings. Here's Why.

Cardinal Health stock jumped Tuesday after the medical wholesaler's fiscal 2027 guidance handily beat Wall Street's expectations. Continue Reading

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

MacroGenics, Inc. ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license …

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci Corporation Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half …

AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk

AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the …

NovelMed Advances NM5072 for Multiple Ocular Disorders

NovelMed Therapeutics Inc Key Highlights Multi-indication precedent: Biogen's approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan. Primate proof of concept: A single intravitreal dose of NM5072 reduced CNV, hemorrhage, and retinal fibrosis in …

Medtronic (MDT) Wins Analyst Upgrades, Is It Fully Priced?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic (MDT) has moved back into focus after multiple analyst upgrades tied to what they describe as the company's strongest annual revenue growth …

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's …

Stocks Mostly Higher in Hopes for a Deal to Reopen Hormuz

The S&P 500 Index ($SPX) (SPY) today is up +0.10%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.05%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.15%. September E-mini S&P futures (ESU26) are up +0.12%, and September E-mini Nasdaq futures (NQU26) …

Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences

argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, …

Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. …

Health Net Providing Special Assistance to Members and Providers Affected by Gann Fire in Calaveras County

SACRAMENTO, Calif., Aug. 11, 2026 /PRNewswire/ -- Following Gov. Newsom's declaration of a State of Emergency in Calaveras County, Health Net, one of California's most experienced Medi-Cal managed care health plans and company of Centene Corporation (NYSE: CNC), is taking immediate action to support …

Raymond James Is Betting Big on These 2 ‘Strong Buy’ Stocks

The S&P 500 is now sitting just below its record high, with another strong earnings season helping stocks remain near their highs. The strength has not been limited to just a handful of companies either, with most S&P 500 sectors contributing to earnings growth …

Arrow Exploration confirms four zones at Icaco 3, opens up ~10 new drilling locations

Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott tells Proactive's Stephen Gunnion that the Icaco 3 well has confirmed up to four hydrocarbon-bearing zones in the Icaco extension of the Tapir Block in Colombia, opening almost 10 additional development locations across the Ubaque, …